Sangamo Therapeutics Stock Price, News & Analysis (NASDAQ:SGMO)

$24.95 -0.45 (-1.77 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$24.95
Today's Range$24.66 - $26.85
52-Week Range$3.65 - $27.50
Volume3.83 million shs
Average Volume2.16 million shs
Market Capitalization$2.11 billion
P/E Ratio-35.14
Dividend YieldN/A
Beta2.87

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:SGMO
CUSIP80067710
Phone+1-510-9706000

Debt

Debt-to-Equity Ratio0.02%
Current Ratio5.64%
Quick Ratio5.64%

Price-To-Earnings

Trailing P/E Ratio-35.1408450704225
Forward P/E Ratio-34.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.39 million
Price / Sales108.76
Cash FlowN/A
Price / CashN/A
Book Value$1.93 per share
Price / Book12.93

Profitability

Trailing EPS($0.71)
Net Income$-71,650,000.00
Net Margins-157.66%
Return on Equity-31.81%
Return on Assets-23.84%

Miscellaneous

Employees131
Outstanding Shares84,520,000

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.03. The biopharmaceutical company had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company's revenue was up 46.6% on a year-over-year basis. During the same period last year, the business earned ($0.14) EPS. View Sangamo Therapeutics' Earnings History.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2018?

6 analysts have issued 12 month target prices for Sangamo Therapeutics' stock. Their forecasts range from $6.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $19.80 in the next twelve months. View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (1/5/2018)
  • 2. Cowen Inc analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
  • 3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

  • Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Kathy Y. Yi, Chief Financial Officer, Senior Vice President (Age 45)
  • Heather D. Turner, Senior Vice President, General Counsel (Age 43)
  • Edward R. Conner M.D., Senior Vice President and Chief Medical Officer (Age 44)
  • Curt Herberts III, Senior Vice President and Chief Business Officer (Age 36)
  • Roger Jeffs Ph.D., Director
  • Joseph S. Zakrzewski, Director (Age 54)
  • Robert F. Carey, Independent Director (Age 58)
  • Stephen G. Dilly M.D. Ph.D., Independent Director (Age 57)
  • Steven J. Mento Ph.D., Independent Director (Age 65)

Who owns Sangamo Therapeutics stock?

Sangamo Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.13%), Wasatch Advisors Inc. (5.56%), Bogle Investment Management L P DE (1.14%), Teachers Advisors LLC (1.12%), Alexandria Capital LLC (1.10%) and Goldman Sachs Group Inc. (1.08%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Who sold Sangamo Therapeutics stock? Who is selling Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Millennium Management LLC, Wasatch Advisors Inc., Altrinsic Global Advisors LLC, Royce & Associates LP, Bain Capital Public Equity Management LLC, Bogle Investment Management L P DE and Nexthera Capital LP. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Curt A Herberts III, Edward R Conner, Saira Ramasastry, Steven J Mento and William R Ringo. View Insider Buying and Selling for Sangamo Therapeutics.

Who bought Sangamo Therapeutics stock? Who is buying Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Alexandria Capital LLC, Tocqueville Asset Management L.P., Goldman Sachs Group Inc., Two Sigma Advisers LP, Two Sigma Investments LP, TIAA CREF Investment Management LLC, BlackRock Inc. and Teachers Advisors LLC. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $24.95.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $2.11 billion and generates $19.39 million in revenue each year. The biopharmaceutical company earns $-71,650,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. Sangamo Therapeutics employs 131 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 Canal Blvd, RICHMOND, CA 94804-3559, United States. The biopharmaceutical company can be reached via phone at +1-510-9706000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (SGMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sangamo Therapeutics (NASDAQ:SGMO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.80$19.80$18.60$9.67
Price Target Upside: 1.02% upside10.92% upside23.18% upside14.40% upside

Sangamo Therapeutics (NASDAQ:SGMO) Consensus Price Target History

Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018WedbushReiterated RatingNeutral$6.00HighView Rating Details
1/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00HighView Rating Details
11/22/2017BarclaysInitiated CoverageOverweight$20.00N/AView Rating Details
10/13/2017Jefferies GroupReiterated RatingBuy$18.00N/AView Rating Details
9/5/2017Wells Fargo & CoReiterated RatingOutperform$20.00 -> $30.00LowView Rating Details
3/22/2017CowenReiterated RatingBuyHighView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Sangamo Therapeutics (NASDAQ:SGMO) Earnings History and Estimates Chart

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018Q4 2017($0.18)($0.15)$11.10 million$13.08 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.19)($0.15)$10.37 million$11.81 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.17)$5.82 million$8.30 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)($0.12)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.15)($0.19)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.08)($0.09)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.09)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.07)($0.05)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.13)($0.12)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.15)($0.11)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.10)($0.17)ViewN/AView Earnings Details
2/4/2009Q4 2008($0.15)($0.06)ViewN/AView Earnings Details
10/29/2008Q3 2008($0.17)($0.15)ViewN/AView Earnings Details
7/23/2008Q2 2008($0.17)($0.18)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.16)($0.20)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.12)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sangamo Therapeutics (NASDAQ:SGMO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.25)($0.25)($0.25)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 68.93%
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Edward R. ConnerVPSell5,000$18.49$92,450.00View SEC Filing  
2/1/2018Curt A Herberts IIIVPSell15,000$20.59$308,850.0029,625View SEC Filing  
2/1/2018Steven J MentoDirectorSell11,520$20.59$237,196.805,000View SEC Filing  
1/8/2018Edward R. ConnerVPSell5,000$17.11$85,550.00View SEC Filing  
1/3/2018Curt A Herberts IIIVPSell15,000$17.26$258,900.0013,015View SEC Filing  
12/6/2017Edward R ConnerVPSell5,000$16.24$81,200.005,000View SEC Filing  
12/4/2017Curt A Herberts IIIVPSell11,803$18.00$212,454.0027,636View SEC Filing  
12/1/2017Curt A. Herberts IIIVPSell16,630$16.13$268,241.90View SEC Filing  
11/17/2017Saira RamasastryDirectorSell5,000$14.67$73,350.005,000View SEC Filing  
10/2/2017Curt A Herberts IIIVPSell15,000$15.25$228,750.00View SEC Filing  
9/20/2017William R RingoDirectorSell31,000$14.37$445,470.0031,800View SEC Filing  
9/1/2017Curt A Herberts IIIVPSell15,000$15.00$225,000.0015,833View SEC Filing  
8/14/2017Curt A Herberts IIIVPSell11,474$10.44$119,788.5623,991View SEC Filing  
7/14/2017Curt A Herberts IIIVPSell15,000$10.00$150,000.0035,517View SEC Filing  
6/1/2017Curt A. Herberts IIIVPSell2,000$6.80$13,600.00View SEC Filing  
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00295,000View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00109,347View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.0097,015View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00218,160View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00295,000View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00225,347View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.0097,015View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00109,347View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00295,000View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.3123,563View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00295,000View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.0097,015View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00227,347View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00109,347View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.0097,015View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00330,000View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00209,219View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00330,000View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.0090,000View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.0084,798View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00330,000View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00209,219View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.0090,000View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines

Source:
DateHeadline
Noteworthy Thursday Option Activity: GS, SGMO, NVDA - Nasdaq.com - NasdaqNoteworthy Thursday Option Activity: GS, SGMO, NVDA - Nasdaq.com - Nasdaq
www.nasdaq.com - February 23 at 8:35 AM
Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE/Gilead ... - Seeking AlphaSangamo Therapeutics: Great Start To 2018 - $3 Billion KITE/Gilead ... - Seeking Alpha
seekingalpha.com - February 23 at 8:35 AM
Meet Gilead and Sangamo’s Next Big Cancer CollaborationMeet Gilead and Sangamo’s Next Big Cancer Collaboration
247wallst.com - February 22 at 5:30 PM
Sangamo Therapeutics Makes Double-Digit Gain On Gilead DealSangamo Therapeutics Makes Double-Digit Gain On Gilead Deal
finance.yahoo.com - February 22 at 5:30 PM
Sangamo in $3 billion gene-editing deal with GileadSangamo in $3 billion gene-editing deal with Gilead
finance.yahoo.com - February 22 at 5:30 PM
Sangamo Therapeutics (SGMO) Announces Quarterly  Earnings ResultsSangamo Therapeutics (SGMO) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 5:12 PM
Gileads Kite (GILD) and Sangamo Therapeutics (SGMO) Announce Pact to Develop Next-Generation Engineered Cell ... - StreetInsider.comGilead's Kite (GILD) and Sangamo Therapeutics (SGMO) Announce Pact to Develop Next-Generation Engineered Cell ... - StreetInsider.com
www.streetinsider.com - February 22 at 8:30 AM
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of CancerKite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
finance.yahoo.com - February 22 at 8:30 AM
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial ResultsSangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results
finance.yahoo.com - February 22 at 8:30 AM
Gileads Kite and Sangamo Therapeutics to collaborate on engineered cell therapies for cancerGilead's Kite and Sangamo Therapeutics to collaborate on engineered cell therapies for cancer
finance.yahoo.com - February 22 at 8:30 AM
Sangamo Therapeutics (SGMO) Set to Announce Earnings on WednesdaySangamo Therapeutics (SGMO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:40 AM
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2017 Conference Call and WebcastSangamo Therapeutics Announces Fourth Quarter and Full Year 2017 Conference Call and Webcast
finance.yahoo.com - February 20 at 8:25 AM
Sangamo Therapeutics (SGMO) Upgraded to "Strong-Buy" by BidaskClubSangamo Therapeutics (SGMO) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - February 17 at 8:46 AM
 Analysts Expect Sangamo Therapeutics Inc (SGMO) to Post -$0.18 EPS Analysts Expect Sangamo Therapeutics Inc (SGMO) to Post -$0.18 EPS
www.americanbankingnews.com - February 14 at 11:26 AM
Wedbush Weighs in on Sangamo Therapeutics Incs FY2022 Earnings (SGMO)Wedbush Weighs in on Sangamo Therapeutics Inc's FY2022 Earnings (SGMO)
www.americanbankingnews.com - February 13 at 4:52 PM
BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice PresidentBRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President
www.reuters.com - February 13 at 3:50 PM
Sangamo Presents Oncology Genome Editing Capabilities at Keystone Symposium on Emerging Cellular TherapiesSangamo Presents Oncology Genome Editing Capabilities at Keystone Symposium on Emerging Cellular Therapies
finance.yahoo.com - February 13 at 9:54 AM
Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General CounselSangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General Counsel
finance.yahoo.com - February 13 at 9:54 AM
Sangamo Therapeutics (SGMO) Earns "Neutral" Rating from WedbushSangamo Therapeutics (SGMO) Earns "Neutral" Rating from Wedbush
www.americanbankingnews.com - February 12 at 11:52 AM
What Investors Should Know about Pfizer’s Recent DevelopmentsWhat Investors Should Know about Pfizer’s Recent Developments
finance.yahoo.com - February 12 at 9:46 AM
Why Sangamo Therapeutics Stock Soared 27% in JanuaryWhy Sangamo Therapeutics Stock Soared 27% in January
finance.yahoo.com - February 8 at 3:48 PM
Heres Why Sangamo Therapeutics Rose as Much as 13.7% TodayHere's Why Sangamo Therapeutics Rose as Much as 13.7% Today
www.fool.com - February 8 at 8:18 AM
Here's Why Sangamo Therapeutics Rose as Much as 13.7% TodayHere's Why Sangamo Therapeutics Rose as Much as 13.7% Today
finance.yahoo.com - February 8 at 8:18 AM
Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 SharesSangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares
www.americanbankingnews.com - February 8 at 12:48 AM
Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposiumSangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium
finance.yahoo.com - February 7 at 9:56 AM
Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 15,000 Shares of StockInsider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 15,000 Shares of Stock
www.americanbankingnews.com - February 5 at 9:32 PM
Steven J. Mento Sells 11,520 Shares of Sangamo Therapeutics Inc (SGMO) StockSteven J. Mento Sells 11,520 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - February 5 at 9:28 PM
Sangamo Therapeutics Inc (SGMO) Receives Consensus Recommendation of "Buy" from BrokeragesSangamo Therapeutics Inc (SGMO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 11:49 AM
$11.28 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter$11.28 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
www.americanbankingnews.com - January 30 at 6:18 AM
Sangamo Therapeutics (SGMO) Stock Rating Upgraded by BidaskClubSangamo Therapeutics (SGMO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 28 at 11:54 PM
Technical Perspectives on Biotech Stocks -- Ultragenyx Pharma, Regeneron ...Technical Perspectives on Biotech Stocks -- Ultragenyx Pharma, Regeneron ...
www.prnewswire.com - January 18 at 11:53 AM
Edward R. Conner Sells 5,000 Shares of Sangamo Therapeutics Inc (SGMO) StockEdward R. Conner Sells 5,000 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - January 10 at 8:00 PM
Heres Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017
www.fool.com - January 9 at 11:53 AM
Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017
finance.yahoo.com - January 9 at 11:16 AM
Sangamo Therapeutics (SGMO) Announces Key Priorities & Catalysts for 2018 - StreetInsider.comSangamo Therapeutics (SGMO) Announces Key Priorities & Catalysts for 2018 - StreetInsider.com
www.streetinsider.com - January 8 at 3:37 PM
Sangamo Therapeutics Outlines 2018 Key Priorities And Catalysts At J.P. Morgan Healthcare ConferenceSangamo Therapeutics Outlines 2018 Key Priorities And Catalysts At J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 10:58 AM
Sangamo Therapeutics (SGMO) Downgraded to "Hold" at Zacks Investment ResearchSangamo Therapeutics (SGMO) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 7 at 8:56 AM
Sangamo Therapeutics To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)Sangamo Therapeutics To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 6 at 3:33 PM
Sangamo Therapeutics, Inc. (SGMO) Given Average Rating of "Buy" by BrokeragesSangamo Therapeutics, Inc. (SGMO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 11:42 AM
Sangamo Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare ConferenceSangamo Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 10:44 AM
Curt A. Herberts III Sells 15,000 Shares of Sangamo Therapeutics, Inc. (SGMO) StockCurt A. Herberts III Sells 15,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Sangamo Therapeutics (SGMO) Given a $25.00 Price Target at Piper Jaffray CompaniesSangamo Therapeutics (SGMO) Given a $25.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - January 4 at 6:40 PM
Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M Upfront - StreetInsider.comSangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M Upfront - StreetInsider.com
www.streetinsider.com - January 3 at 10:58 AM
Sangamo Jumps on Newest Pfizer CollaborationSangamo Jumps on Newest Pfizer Collaboration
finance.yahoo.com - January 3 at 10:58 AM
Sangamo Therapeutics (SGMO) Upgraded to "Buy" at BidaskClubSangamo Therapeutics (SGMO) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - December 29 at 6:32 AM
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino BiopharmaceuticalThe Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
finance.yahoo.com - December 28 at 10:17 AM
4 Biotech Stocks Ready to Crush the Market in 20184 Biotech Stocks Ready to Crush the Market in 2018
www.nasdaq.com - December 27 at 1:27 PM
Zacks: Analysts Anticipate Sangamo Therapeutics, Inc. (SGMO) Will Post Quarterly Sales of $11.28 MillionZacks: Analysts Anticipate Sangamo Therapeutics, Inc. (SGMO) Will Post Quarterly Sales of $11.28 Million
www.americanbankingnews.com - December 27 at 5:00 AM
Zacks: Analysts Expect Sangamo Therapeutics, Inc. (SGMO) to Announce -$0.18 Earnings Per ShareZacks: Analysts Expect Sangamo Therapeutics, Inc. (SGMO) to Announce -$0.18 Earnings Per Share
www.americanbankingnews.com - December 25 at 7:26 PM
Sangamo Therapeutics Inc (NASDAQ:SGMO): Has Recent Earnings Growth Beaten Long-Term Trend?Sangamo Therapeutics Inc (NASDAQ:SGMO): Has Recent Earnings Growth Beaten Long-Term Trend?
finance.yahoo.com - December 21 at 3:36 PM

SEC Filings

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sangamo Therapeutics (NASDAQ:SGMO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sangamo Therapeutics (NASDAQ SGMO) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.